![Clinical and Theoretical Implications of 5-HT2 and D2 Receptor Occupancy of Clozapine, Risperidone, and Olanzapine in Schizophrenia | American Journal of Psychiatry Clinical and Theoretical Implications of 5-HT2 and D2 Receptor Occupancy of Clozapine, Risperidone, and Olanzapine in Schizophrenia | American Journal of Psychiatry](https://ajp.psychiatryonline.org/cms/10.1176/ajp.1999.156.issue-2/asset/1497fe0d-f014-7fe0-8f01-97fe0d8f0149/ajp.1999.156.issue-2.cover.jpg)
Clinical and Theoretical Implications of 5-HT2 and D2 Receptor Occupancy of Clozapine, Risperidone, and Olanzapine in Schizophrenia | American Journal of Psychiatry
![Clinical and Theoretical Implications of 5-HT2 and D2 Receptor Occupancy of Clozapine, Risperidone, and Olanzapine in Schizophrenia | American Journal of Psychiatry Clinical and Theoretical Implications of 5-HT2 and D2 Receptor Occupancy of Clozapine, Risperidone, and Olanzapine in Schizophrenia | American Journal of Psychiatry](https://ajp.psychiatryonline.org/cms/10.1176/ajp.156.2.286/asset/images/medium/aj17f1.jpeg)
Clinical and Theoretical Implications of 5-HT2 and D2 Receptor Occupancy of Clozapine, Risperidone, and Olanzapine in Schizophrenia | American Journal of Psychiatry
![PDF) Imaging the norepinephrine transporter with positron emission tomography: Initial human studies with (S,S)-[18F]FMeNER-D2 PDF) Imaging the norepinephrine transporter with positron emission tomography: Initial human studies with (S,S)-[18F]FMeNER-D2](https://i1.rgstatic.net/ii/profile.image/1071192396013570-1632403577507_Q64/P-David-Mozley.jpg)
PDF) Imaging the norepinephrine transporter with positron emission tomography: Initial human studies with (S,S)-[18F]FMeNER-D2
![PDF) Imaging the norepinephrine transporter with positron emission tomography: Initial human studies with (S,S)-[18F]FMeNER-D2 PDF) Imaging the norepinephrine transporter with positron emission tomography: Initial human studies with (S,S)-[18F]FMeNER-D2](https://i1.rgstatic.net/ii/profile.image/1082097968128000-1635003668065_Q64/Masahiro-Fujita-11.jpg)
PDF) Imaging the norepinephrine transporter with positron emission tomography: Initial human studies with (S,S)-[18F]FMeNER-D2
![PDF) Imaging the norepinephrine transporter with positron emission tomography: Initial human studies with (S,S)-[18F]FMeNER-D2 PDF) Imaging the norepinephrine transporter with positron emission tomography: Initial human studies with (S,S)-[18F]FMeNER-D2](https://i1.rgstatic.net/publication/5934874_Imaging_the_norepinephrine_transporter_with_positron_emission_tomography_Initial_human_studies_with_SS-18FFMeNER-D2/links/00b7d5153eadf84264000000/largepreview.png)
PDF) Imaging the norepinephrine transporter with positron emission tomography: Initial human studies with (S,S)-[18F]FMeNER-D2
![Clinical and Theoretical Implications of 5-HT2 and D2 Receptor Occupancy of Clozapine, Risperidone, and Olanzapine in Schizophrenia | American Journal of Psychiatry Clinical and Theoretical Implications of 5-HT2 and D2 Receptor Occupancy of Clozapine, Risperidone, and Olanzapine in Schizophrenia | American Journal of Psychiatry](https://ajp.psychiatryonline.org/cms/10.1176/ajp.156.2.286/asset/images/medium/aj17f2.jpeg)
Clinical and Theoretical Implications of 5-HT2 and D2 Receptor Occupancy of Clozapine, Risperidone, and Olanzapine in Schizophrenia | American Journal of Psychiatry
![PDF) Imaging the norepinephrine transporter with positron emission tomography: Initial human studies with (S,S)-[18F]FMeNER-D2 PDF) Imaging the norepinephrine transporter with positron emission tomography: Initial human studies with (S,S)-[18F]FMeNER-D2](https://i1.rgstatic.net/ii/profile.image/11431281081308095-1661707245743_Q64/Sylvain-Houle-3.jpg)
PDF) Imaging the norepinephrine transporter with positron emission tomography: Initial human studies with (S,S)-[18F]FMeNER-D2
![PDF) Imaging the norepinephrine transporter with positron emission tomography: Initial human studies with (S,S)-[18F]FMeNER-D2 PDF) Imaging the norepinephrine transporter with positron emission tomography: Initial human studies with (S,S)-[18F]FMeNER-D2](https://i1.rgstatic.net/ii/profile.image/277867117203461-1443260091303_Q64/Joel-Mercier-2.jpg)
PDF) Imaging the norepinephrine transporter with positron emission tomography: Initial human studies with (S,S)-[18F]FMeNER-D2
![PDF) Imaging the norepinephrine transporter with positron emission tomography: Initial human studies with (S,S)-[18F]FMeNER-D2 PDF) Imaging the norepinephrine transporter with positron emission tomography: Initial human studies with (S,S)-[18F]FMeNER-D2](https://i1.rgstatic.net/ii/profile.image/631107632504835-1527479193687_Q64/Balazs-Gulyas-2.jpg)
PDF) Imaging the norepinephrine transporter with positron emission tomography: Initial human studies with (S,S)-[18F]FMeNER-D2
![PDF) Imaging the norepinephrine transporter with positron emission tomography: Initial human studies with (S,S)-[18F]FMeNER-D2 PDF) Imaging the norepinephrine transporter with positron emission tomography: Initial human studies with (S,S)-[18F]FMeNER-D2](https://www.researchgate.net/profile/Anu-Airaksinen/publication/5934874/figure/fig1/AS:601736741924864@1520476627157/Mean-whole-brain-uptake-over-time-expressed-as-a-percentage-of-injected-dose-ID-of_Q320.jpg)
PDF) Imaging the norepinephrine transporter with positron emission tomography: Initial human studies with (S,S)-[18F]FMeNER-D2
![Targeting the endocannabinoid system: a predictive, preventive, and personalized medicine-directed approach to the management of brain pathologies | EPMA Journal Targeting the endocannabinoid system: a predictive, preventive, and personalized medicine-directed approach to the management of brain pathologies | EPMA Journal](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs13167-020-00203-4/MediaObjects/13167_2020_203_Fig1_HTML.png)